Insights on Clinical Trials

  1. Killing Excel: The Quiet Crisis In Clinical Trials 8/13/2026

    Stop relying on spreadsheets for critical clinical trial decisions. Learn how standardizing vendor selection eliminates inefficiencies and protects budgets.

  2. Keep Your Vendors On Track: The 4 KPIs That Matter Most 8/13/2026

    Master clinical vendor management with four key pillars: time, money, quality, and relationships. Learn which essential KPIs keep your trial timelines and budgets on track.

  3. Mastering Clinical Trial Forecasting Through Continuous Learning 8/13/2026

    Stop treating trial budgets as fixed predictions. Discover how top teams refine financial forecasts by tracking shifting assumptions to improve governance and build trust.

  4. Cagey Sponsors, Defensive Vendors: Observations On How Transparency Breaks Down 8/13/2026

    Discover how hidden operational uncertainties trigger defensive pricing and scope disputes—and how early transparency builds stable, high-performing research partnerships.

  5. A System For Better Vendor Relationships 8/13/2026

    Shift your clinical trial strategy with zero-cost habits that build trust, protect trial continuity, and transform routine supplier management into resilient, high-performing partnerships.

  6. When Early CRO Wins Quietly Create Long-Term Study Risk 8/13/2026

    Discover how overemphasizing early trial milestones can compromise long-term execution. Learn key strategies to build sustainable operational frameworks for lasting study success.

  7. AI Tools In Informed Consent: What Sponsors Need To Know About Risk 8/1/2026

    AI tools carry different risks. See how they can impact participant communications, where bias and inaccuracies emerge, and why human review is critical to protecting study integrity.

  8. Demonstrating The Value Of Investigational Drug Services Through Time-Based Metrics 7/29/2026

    Learn how adopting time-based metrics helps research teams accurately track workload, optimize staffing, and justify trial budgets.

  9. ImvivaBio's Trial For Off-The-Shelf CAR-T Strategy For Aggressive Malignancies 7/28/2026

    ImvivaBio CMO Jan Davidson-Moncada, MD, Ph.D., discusses the company's Phase 1b/2 study for aggressive T-cell malignancies, explaining their unmet need, the rationale for an allogeneic approach, and how they plan to address immune rejection.

  10. Drug Development Plan Explained: DPP Templates And Examples 7/27/2026

    Only 6.7% of Phase 1 drugs reach approval. A well-structured Drug Development Plan (DDP) can meaningfully improve your odds — learn exactly how to build one.